CNS Pharmaceuticals (CNSP)
NASDAQ:CNSP
Top Page
CNS Pharmaceuticals
(NASDAQ:CNSP)
Select Model
Select Model
Rating:42Neutral
Price Target:
$2.50
▼(-58.40% Downside)
Action:ReiteratedDate:04/01/26
The score is primarily held down by weak financial performance (no revenue, recurring losses, and ongoing cash burn) and bearish technical conditions (price below key moving averages with negative MACD). Valuation metrics provide limited support due to a negative P/E and no dividend, while recent positive corporate actions modestly offset risks but are not yet reflected in operating results.
Positive Factors
Management quality
The company has installed an experienced executive slate (new CFO, CMO, CBO, CTO) with proven biotech, clinical and deal-making backgrounds. Sustained leadership strength improves clinical program design, capital strategy and BD execution, raising odds of successful asset acquisitions and program advancement over months.
Negative Factors
Persistent cash burn
Consistent negative operating and free cash flow demonstrates ongoing cash burn to fund development with no revenue cushion. Over 2-6 months this keeps the company dependent on external financing, which can dilute shareholders and constrain strategic optionality if capital markets deteriorate.
Read all positive and negative factors
Positive Factors
Negative Factors
Management quality
The company has installed an experienced executive slate (new CFO, CMO, CBO, CTO) with proven biotech, clinical and deal-making backgrounds. Sustained leadership strength improves clinical program design, capital strategy and BD execution, raising odds of successful asset acquisitions and program advancement over months.
Read all positive factors
CNS Pharmaceuticals (CNSP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.77M
Dividend YieldN/A
Average Volume (3M)16.54K
Price to Earnings (P/E)―
Beta (1Y)2.38
Revenue GrowthN/A
EPS Growth99.87%
CountryUS
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.76
Shares Outstanding811,449
10 Day Avg. Volume15,052
30 Day Avg. Volume16,543
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.51
Price to Sales (P/S)0.00
P/FCF Ratio-0.17
Enterprise Value/Market Cap-3.18
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.35
Forecast
1Y Price Target
$10.00Price Target Upside66.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-6.33
Revenue Forecast (FY)$40.76M
CNS Pharmaceuticals Business Overview & Revenue Model
Company Description
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline ...
How the Company Makes Money
null...
CNS Pharmaceuticals Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -3.31K | -4.13K | -11.76K | -13.07K |
| EBITDA | -15.83M | -14.84M | -18.86M | -15.26M | -14.47M |
| Net Income | -15.85M | -14.86M | -18.85M | -15.27M | -14.50M |
Balance Sheet | |||||
| Total Assets | 8.62M | 8.70M | 1.70M | 13.05M | 8.76M |
| Cash, Cash Equivalents and Short-Term Investments | 7.20M | 6.46M | 548.72K | 10.06M | 5.00M |
| Total Debt | 328.57K | 326.07K | 300.81K | 409.97K | 387.79K |
| Total Liabilities | 4.10M | 2.52M | 6.13M | 4.92M | 2.14M |
| Stockholders Equity | 4.52M | 6.18M | -4.43M | 8.13M | 6.62M |
Cash Flow | |||||
| Free Cash Flow | -13.83M | -17.12M | -14.14M | -10.56M | -13.54M |
| Operating Cash Flow | -13.81M | -17.11M | -14.14M | -10.56M | -13.54M |
| Investing Cash Flow | -18.18K | -4.19K | -3.90K | -4.42K | -5.75K |
| Financing Cash Flow | 14.57M | 23.03M | 4.64M | 15.61M | 4.51M |
CNS Pharmaceuticals Technical Analysis
Negative
6.01
Price Trends
3.16
Negative
4.82
Negative
6.52
Negative
Market Momentum
-0.29
Negative
34.83
Neutral
13.24
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CNSP, the sentiment is Negative. The current price of 6.01 is above the 20-day moving average (MA) of 2.35, above the 50-day MA of 3.16, and below the 200-day MA of 6.52, indicating a bearish trend. The MACD of -0.29 indicates Negative momentum. The RSI at 34.83 is Neutral, neither overbought nor oversold. The STOCH value of 13.24 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CNSP.
CNS Pharmaceuticals Risk Analysis
CNS Pharmaceuticals disclosed 39 risk factors in its most recent earnings report. CNS Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
CNS Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | $1.52M | -0.19 | -63.03% | ― | -100.00% | 86.75% | |
43 Neutral | $3.54M | -0.15 | -381.74% | ― | ― | 98.22% | |
42 Neutral | $1.77M | -0.10 | -197.11% | ― | ― | 99.87% | |
| ― | $2.61M | -0.17 | -168.95% | ― | ― | 90.27% | |
42 Neutral | $2.37M | ― | -82.17% | ― | -3.27% | 51.83% |
* Healthcare Sector Average
CNSP
CNS Pharmaceuticals
2.18
-13.18
-85.81%
BDRX
Biodexa Pharmaceuticals
3.36
-79.14
-95.93%
OGEN
Oragenics
0.60
-5.08
-89.39%
INM
InMed Pharmaceuticals
0.72
-1.93
-72.92%
GRI
GRI Bio
2.45
-39.83
-94.21%
CNS Pharmaceuticals Corporate Events
Business Operations and Strategy
CNS Pharmaceuticals Unveils Strategic Pivot to Broader Oncology
Positive
Mar 11, 2026
On March 11, 2026, CNS Pharmaceuticals posted a new investor presentation outlining a strategic pivot driven by a newly installed executive team with deep neurology, oncology, and rare disease experience. The company is redirecting its focus from ...
Business Operations and StrategyExecutive/Board Changes
CNS Pharmaceuticals Appoints New Chief Medical Officer
Positive
Mar 2, 2026
On February 26, 2026, CNS Pharmaceuticals, Inc. appointed veteran biotechnology executive Lynne Kelley as Chief Medical Officer effective March 2, 2026, under an employment agreement that provides a $450,000 base salary, performance-based bonus el...
Business Operations and StrategyExecutive/Board Changes
CNS Pharmaceuticals Restructures Finance Leadership, Appoints New CFO
Positive
Feb 17, 2026
On February 10, 2026, CNS Pharmaceuticals entered into an employment agreement with Steve O’Loughlin to become Chief Financial Officer effective March 2, 2026, with a $450,000 base salary, performance-based bonus opportunity, equity incentiv...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.